2076 - Wahroonga - Sydney Adventist Hospital (COMPLETED)2485 - Tweed Heads - The Tweed Hospital (COMPLETED)2640 - Albury - Border Medical Oncology Research Unit (COMPLETED)

3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (COMPLETED)3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (COMPLETED)

QLD4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)

ACTRN12625000361404

A Phase 1, Multicentre, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FO-004 in Patients with advanced solid tumours.

ACTRN12625000309482

Accelerated Partial breast irradiation Using external beam Volumetric Modulated Arc Therapy (VMAT): a randomised non-inferiority trial of 30 Gy versus 26 Gy in five fractions investigating patient-reported outcomes. (PUMA)

ACTRN12624001230549

An assessment of cancer outcomes post cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases with the use of a personalised aproach to choice of intraperitoneal chemotherapy agent individualised to a patient's specific tumour sensitivity in-vitro.

ACTRN12623001077651

A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies - Module 2. (EMITT-1)

ACTRN12623000104651

Phase I Trial of the Safety and Efficacy of Deflexifol for Refractory or Recurrent Paediatric Central Nervous System (CNS) Tumours (DART)

ACTRN12622000083796

Medicinal Cannabis (MedCan 3) – a randomised, multicentre, double blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer (20))

NA

ACTRN12622000037707

A prospective, multicentre, randomised, blinded, two-arm parallel trial of Medicinal Cannabis Products for symptom burden in children with advanced cancer (MINI)

ACTRN12621001419853

A Phase 1 Dose Escalation and Dose Expansion Open-label, Multicenter, Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer (OP-1250-002)

ACTRN12621000639820

The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (PARAGON-II) .

ACTRN12621000227897

Not Applicable

Feasibility of Magnetic Resonance Imaging guided stereotactic reirradiation in patients who have previously received radiation for prostate cancer and have biochemical and local recurrence of cancer within the prostate (PRIUS-MR)

ACTRN12619000079145

A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (The-AutoCAR19-Trial)

NCT06909825

A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) (FPI-2265-203)

NCT06712355

A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer (BNT327-03)

NCT06614192

AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff (M24-064)

PD-1/PD-L1	33%
PD-1	29%
oestrogen axis	12%
PD-L1	9%
TIGIT	8%
VEGF	8%
CDK4	8%
CDK6	8%
ERBB2	7%
AR	7%
androgen axis	7%
ER	7%
CYP17A1	5%
PARP	5%
KRAS	4%
KRAS G12C	4%
EGFR	4%
CD20	4%
VEGFA	4%
Trop2	4%
CTLA4	3%
cereblon	3%
BTK	3%
Bcl2	3%
PI3K alpha	3%
mTOR	3%
mTORC1	3%
ERBB3	3%
FR-alpha	3%
Nectin4	3%
PARP1-selective	3%
LAG3	3%
KLK2	2%
ERAP1	2%
BCMA	2%
PI3K	2%
mTORC2	2%
LHRH	2%
MEK	2%
HPK1	2%
WEE1	2%
CD38	1%
proteasome	1%
PI3K delta	1%
CLDN6	1%
CEACAM5	1%
TLR7/TLR8	1%
FGFR2	1%
FGFR2b	1%
PRMT5	1%
EZH2	1%
ER alpha	1%
AKT	1%
AKT1	1%
B7H3	1%
STAT3	1%
TTR	1%
BRAF	1%
CRAF	1%
FAK	1%
RAF	1%
pan-RAF	1%
MUC18	1%
DNA-dependent protein kinase	1%
CD93	1%
gp100	1%
CDK2	1%
CS1	1%
CD44v9	1%
CLDN18.2	1%
CD73	1%
XPO1	1%
CD19	1%
ROR1	1%
SMO	1%
B7H4	1%
TP53	1%
TP53 Y220C	1%
HRAS G12C	1%
NRAS G12C	1%
SHP2	1%
KIT	1%
OX40	1%
PDGFR	1%
RET	1%
VEGFR	1%
VEGFR1	1%
VEGFR2	1%
VEGFR3	1%
CD22	1%
MDM2	1%
GnRH	1%
PSMA	1%
MET	1%

ARTICANZ - Beta (ver 0.91)

Search results

Filters